Payers won’t let these products break the bank.
Ira Studin, PhD
Advertisement
Articles by Ira Studin, PhD
Conditions require a disciplined approach to drug pricing.
Shift focus in orphan and ultra-orphan messaging to clinical benefit.
Supporting health plan clinical preparation and financial modeling.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
US and UK Agree to Zero Tariffs on Pharmaceuticals
2
Strive Pharmacy Breaks Ground on Arizona HQ
3
New HTI-4 Final Rule Sets Path for Modernized Prescribing and Patient Access
4
How DSCSA Compliance Is Unlocking Recall Efficiency
5
